- Home
- RENB vs ONCY Comparison
RENB vs ONCY Comparison
Compare RENB & ONCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RENB
- ONCY
- Stock Information
- Founded
- RENB 2011
- ONCY 1998
- Country
- RENB United States
- ONCY Canada
- Employees
- RENB N/A
- ONCY N/A
- Industry
- RENB Biotechnology: Pharmaceutical Preparations
- ONCY Pharmaceuticals and Biotechnology
- Sector
- RENB Health Care
- ONCY Health Care
- Exchange
- RENB Nasdaq
- ONCY Nasdaq
- Market Cap
- RENB 101.3M
- ONCY 86.1M
- IPO Year
- RENB N/A
- ONCY 1999
- Fundamental
- Price
- RENB $0.50
- ONCY $0.98
- Analyst Decision
- RENB
- ONCY Strong Buy
- Analyst Count
- RENB 0
- ONCY 2
- Target Price
- RENB N/A
- ONCY $4.00
- AVG Volume (30 Days)
- RENB 298.6K
- ONCY 354.7K
- Earning Date
- RENB 11-14-2024
- ONCY 11-12-2024
- Dividend Yield
- RENB N/A
- ONCY N/A
- EPS Growth
- RENB N/A
- ONCY N/A
- EPS
- RENB N/A
- ONCY N/A
- Revenue
- RENB N/A
- ONCY N/A
- Revenue This Year
- RENB N/A
- ONCY N/A
- Revenue Next Year
- RENB N/A
- ONCY N/A
- P/E Ratio
- RENB N/A
- ONCY N/A
- Revenue Growth
- RENB N/A
- ONCY N/A
- 52 Week Low
- RENB $0.40
- ONCY $0.84
- 52 Week High
- RENB $5.25
- ONCY $1.75
- Technical
- Relative Strength Index (RSI)
- RENB 44.10
- ONCY 39.57
- Support Level
- RENB $0.46
- ONCY $1.01
- Resistance Level
- RENB $0.56
- ONCY $1.09
- Average True Range (ATR)
- RENB 0.08
- ONCY 0.06
- MACD
- RENB -0.01
- ONCY -0.02
- Stochastic Oscillator
- RENB 18.72
- ONCY 4.76
About RENB Renovaro Biosciences Inc.
Renovaro Inc is a biopharmaceutical company. It is engaged in developing new immunotherapies to combat cancer and developing a predicative artificial intelligence-based diagnostic methodology for the use of earlier cancer detection.
About ONCY Oncolytics Biotech Inc.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatment. The other projects in the company's pipeline include, Bracelet-1 for treatment of Breast Cancer, Goblet cohort-1, Goblet cohort-5 for treatment of Gastro-Intestinal Cancer among others.